A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Lilly pill maintains weight loss after switching from injectables in trial

Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
pharmaphorum

Lilly points to long-lasting weight loss with orforglipron

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...
Woman's World on MSN

New weight loss drug beats Ozempic and eases joint pain with 'insane' results, doctors say

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...
STAT

Pharmalittle: We’re reading about Lilly’s obesity pill, pharma deals with Trump, and much more

A Lilly investigational obesity pill largely helped patients maintain their weight loss after they switched from injectable ...
The Economist

What Novo Nordisk, OpenAI and Pop Mart have in common

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, ...